05-840
Anti-IDO (Indoleamine 2,3-Dioxygenase) Antibody, clone 10.1
clone 10.1, Upstate®, from mouse
Synonym(s):
Indoleamine 2,3-dioxygenase, Indoleamine-pyrrole 2,3-dioxygenase, indole 2,3-dioxygenase, indoleamine-pyrrole 2,3 dioxygenase, IDO1
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
10.1, monoclonal
species reactivity
human, mouse
manufacturer/tradename
Upstate®
technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
Gene Information
human ... IDO1(3620)
mouse ... Ido1(15930)
General description
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
Specificity
Recognizes IDO (Indoleamine 2,3- Dioxygenase), Mr 42 kDa.
Immunogen
GST fusion protein corresponding to residues 78-184 of human Indoleamine 2,3- Dioxygenase (IDO). Clone 10.1.
Application
Anti-IDO (Indoleamine 2, 3-Dioxygenase) Antibody, clone 10.1 is an antibody against IDO (Indoleamine 2 for use in IC & WB.
Immunocytochemistry: A previous lot was used by an independent laboratory in Phoenix cells transfected with an expression vector.
Immunohistochemistry: A previous lot of this antibody was used to detect IDO in human retina, primary eye tumor and metastatic liver tumor tissue sections (Chen, P.W., et al. Experimental Eye Research 85(2007) 617-625).
Immunohistochemistry: A previous lot of this antibody was used to detect IDO in human retina, primary eye tumor and metastatic liver tumor tissue sections (Chen, P.W., et al. Experimental Eye Research 85(2007) 617-625).
Quality
Routinely evaluated by Western Blot on untreated and IFNgamma treated (24 hrs) Hela lysates.
Western Blot Analysis:
1:500 dilution of this lot detected IDO on 10 ug of untreated and IFN gamma treated Hela lysates.
Western Blot Analysis:
1:500 dilution of this lot detected IDO on 10 ug of untreated and IFN gamma treated Hela lysates.
Target description
42 kDa
Linkage
Replaces: 04-1056
Physical form
Format: Purified
Purified mouse monoclonal IgG in buffer containing 70% storage buffer 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide and 30% glycerol.
Analysis Note
Control
Human IFN-gamma stimulated HeLa cell lysates, IFN gamma stimulated human peripheral blood lymphocytes.
Human IFN-gamma stimulated HeLa cell lysates, IFN gamma stimulated human peripheral blood lymphocytes.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sewha Kim et al.
Journal of Cancer, 8(1), 124-130 (2017-01-27)
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme involved in tumor immune escape. Blockade of the IDO1 pathway is an emerging modality of cancer immunotherapy. Triple-negative breast cancer (TNBC) lacks established therapeutic targets and may be a good candidate for
David H Munn et al.
Science (New York, N.Y.), 297(5588), 1867-1870 (2002-09-14)
Antigen-presenting cells (APCs) can induce tolerance or immunity. We describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell proliferation in vitro. IDO-positive APCs constituted a discrete subset identified by coexpression of the cell-surface markers
M W Taylor et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 5(11), 2516-2522 (1991-08-01)
Interferons have been shown to be potential anti-cancer agents and to inhibit tumor cell growth in culture. The in vivo mechanism of the anti-proliferative effect may be direct or indirect through the immune system; however, in vitro a primary mechanism
Annabel Meireson et al.
Frontiers in immunology, 12, 736498-736498 (2021-09-25)
Immune escape is an early phenomenon in cancer development/progression. Indoleamine 2,3-dioxygenase 1 (IDO1) is a normal endogenous mechanism of acquired peripheral immune tolerance and may therefore be tumor-promoting. This study investigated the clinical relevance of IDO1 expression by immune cells
Ying Lu et al.
Blood, 119(4), 1075-1085 (2011-12-02)
Allogeneic hematopoietic stem cell transplantation (HSCT) can eradicate chemorefractory leukemia through the graft-versus-leukemia (GVL) activity of donor T cells. However, the clinical success of allo-HSCT is limited by the graft-versus-host disease (GVHD) activity of donor T cells. We have reported
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service